H.B. 385 Summary

• Requires the Ohio Attorney General to investigate prescription insulin drug pricing to ensure adequate consumer protections and determine if additional protections are needed.

• Authorizes the Attorney General to compile and analyze information from insulin manufacturers, health plan issuers, pharmacy benefit managers, and pharmacies regarding business practices, pricing data, and related information.

• Allows the Attorney General to issue civil investigative demands to state departments, health plan issuers, pharmacy benefit managers, drug manufacturers, or pharmacies to obtain necessary materials and data.

• Requires the Attorney General to submit a report within 18 months to the Governor, Superintendent of Insurance, and relevant General Assembly committees detailing findings on insulin pricing practices and variables affecting prices.

• Report must include recommendations for controlling insulin overpricing and improving Ohio's consumer protection laws to prevent deceptive sales practices involving prescription insulin.